Journal article

MMX mesalazine for the induction of remission of mild-to-moderately active ulcerative colitis: efficacy and tolerability in specific patient subpopulations

GR Lichtenstein, MA Kamm, WJ Sandborn, A Lyne, RE Joseph

ALIMENTARY PHARMACOLOGY & THERAPEUTICS | WILEY | Published : 2008

Abstract

BACKGROUND: Two phase III studies have evaluated mesalazine (mesalamine) with MMX (Multi Matrix System) technology in patients with active mild-to-moderate ulcerative colitis. AIM: To determine the efficacy of MMX mesalazine for the induction of clinical and endoscopic remission in specific subgroups of patients with active, mild-to-moderate ulcerative colitis. METHODS: Data from two double-blind, placebo-controlled trials were analysed (517 out-patients). Patients were randomized to receive MMX mesalazine [2.4 g/day (once daily or 1.2 g twice daily) or 4.8 g/day (once daily)] or placebo for 8 weeks. RESULTS: The percentages of patients treated with MMX mesalazine, 2.4 or 4.8 g/day, in clini..

View full abstract